

Use of sodium salt of cyclic β -formylester for synthesis of dihydro-2*H*-furo[2,3-*d*]pyrazolo[3,4-*b*]pyridines and pyrazolo[3,4-*b*]pyrrolo[2,3-*d*]pyridines

Shivaraj P. Patil · Raghunath B. Toche

Received: 5 October 2010 / Accepted: 30 May 2011 / Published online: 28 June 2011
© Springer-Verlag 2011

Abstract The chemoselective reaction of the sodium salt of α -formyl- γ -butyrolactone and 5-aminopyrazole furnished dihydrofuro[2,3-*d*]pyrazolo[3,4-*b*]pyridine at two different reaction conditions, i.e., with NH_4OAc or in refluxing AcOH . The same reactants when refluxed in MeOH and AcOH produced a pyrazolylamino dihydrofuranone derivative. A mixture of 2-chloroethyl-4-chloropyrazolopyridines and dihydrofuro[2,3-*d*]pyrazolo[3,4-*b*]pyridine derivatives was obtained on refluxing the intermediate dihydrofuranone in POCl_3 . A one-step synthesis of tricyclic pyrazolopyrrolopyridines and thienopyrazolopyridines resulted from $\text{S}_{\text{N}}\text{Ar}$ reaction of 2-chloroethyl-4-chloropyrazolopyridines with primary aromatic amines and with thiourea.

Keywords α -Formyl- γ -butyrolactone · Pyrazolopyridines · Pyrazolopyrrolopyridines · Dihydrofuropyrazolopyridines

Introduction

Pyrazolo[3,4-*b*]pyridines have shown several interesting biological and pharmacological applications such as anti-tubercular action [1, 2], activity against Gram-positive and Gram-negative bacteria [3], and adrenocortrophic hormone (ACTH)-releasing factor and corticotrophin-releasing factor (CRF) antagonist activity [4]. A literature survey reveals that pyrido[1,2-*a*]pyrimidines having an ethyl chain also showed interesting biological activity [5–8].

To date, very few reactions involving use of α -formyl- γ -butyrolactone for synthesis of heterocyclic systems have been reported in literature. Several applications of the reaction of cyclic β -ketoesters with primary aromatic amines have been reported, such as the easy introduction of dihydrofuranones [9, 10], 2-chloroethyl/4-chloro functionality in pyridine derivatives, and one-step synthesis of fused tricyclic heteroaromatic systems [9]. The reactions of cyclic β -ketoesters are sensitive to temperature [11] and require mild reaction conditions.

In literature, pyrazolopyridines were obtained by condensation of 5-aminopyrazole with diethoxyethylene malonate [12], 1,3-diketone [13], and α,β -unsaturated ketone [14]. Previously we have used β -ketoesters for synthesis of pyrazolopyridine and obtained the required functionalities at the expected positions [15]. Here, we introduce β -formylester for synthesis of fused heterocycles. Instead of α -formyl- γ -butyrolactone, its sodium salt was used, being prepared by the reaction of γ -butyrolactone with ethyl formate and sodium hydride in dry ether [16]. Ethoxyethylenetetrahydrofuran-2-one also gave a similar reaction [17, 18], but for the preparation of the ethoxyethylenetetrahydrofuran-2-one, chloroethyl formate is required, which is lachrymatory and hence unhealthy for laboratory use. To avoid use of chloroethyl formate, we directly reacted the sodium salt of α -formyl- γ -butyrolactone with 5-aminopyrazole, which gave a facile reaction and better yields of the target molecules.

In this paper we report the chemoselective reactions of the sodium salt of α -formyl- γ -butyrolactone with 5-aminopyrazole under mild reaction conditions. The obtained pyrazolo[3,4-*b*]pyridines have reactive 4-chloro and 5-(2-chloroethyl) substituents which not only increase the pharmacological activity but also facilitate one-step synthesis of tricyclic heterocycles. The strategic substitutions

S. P. Patil · R. B. Toche (✉)
Department of Chemistry, Organic Chemistry Research Centre,
K. T. H. M. College, University of Pune, Gangapur Road,
Nashik 422002, Maharashtra, India
e-mail: raghunath_toche@rediffmail.com

of pyrazolopyridines gave facile and neat reactions with amino and thio compounds to furnish a new class of tricyclic heterocycles such as pyrazolo[3,4-*b*]pyrrolo[2,3-*d*]pyridine in good yield and high purity.

Results and discussion

Intermediate pyrazolylamino dihydrofuranones **3** (Scheme 1) were obtained by condensation of 5-aminopyrazole **1** with the sodium salt of α -formyl- γ -butyrolactone (**2**) in AcOH and MeOH at reflux temperature. The in situ formed free formyl ester generated by the weak acid catalyst undergoes attack of the amino group, yielding the *Z*-enamine **3**. Use of mineral acid furnished a mixture of several products as seen by thin-layer chromatography (TLC). The *Z* stereochemistry of enamine **3** was proved on the basis of a decrease in lactone carbonyl stretching to 1,722–1,718 cm^{-1} due to hydrogen bonding between NH and lactone carbonyl. Also, the ^1H nuclear magnetic resonance (NMR) of compound **3b** showed a multiplet at $\delta = 2.81$ ppm for $=\text{C}-\text{CH}_2$ and a triplet at 4.21 ppm with $J = 8.4$ Hz for CH_2O , which is possible only in the *Z*-isomer.


When compounds **1** and **2** were refluxed in presence of AcOH or NH_4OAc , fused tricyclic dihydrofuro-pyrazolopyridines **5** were formed in 85% yield. Similar reactions with intermediate **3** in POCl_3 also yielded the same compound **5** (Fig. 1). The pyrazolylidihydrofuranones **3** on refluxing in POCl_3 furnished a mixture of compounds **4** and **5** (TLC check), which was separated on column by eluting with chloroform–methanol 9:1 to yield **4** and **5** in 70% and 25% yield, respectively. Analogously, compounds **4b** and

5b were synthesized and assigned the structures shown in Scheme 1.

Compounds **4** on refluxing in sodium ethoxide/ethanol furnished a $\text{S}_{\text{N}}\text{Ar}$ reaction at C4 and E_2 elimination at the side-chain to yield substitution–elimination products **6**. The C4-Cl in pyrazolopyridine **4** was replaced by azide, when compound **4** was heated with sodium azide at 55 °C in dimethylformamide (DMF) and with ethylene glycol in presence of a catalytic amount of triethylamine to yield products **7** and **8**, respectively (Scheme 2).

Advantage of C4-Cl and C3-chloroethyl was also taken to annelate a tetrahydrofuran ring to the pyridine nucleus to yield compounds **5a**, **5b** (Scheme 1). Reaction of compounds **4a**, **4b** with thiourea in acetic acid under reflux condition furnished thienopyrazolopyridines **9a**, **9b** in good yields (Scheme 3). Boiling thiourea with AcOH in situ generates H_2S , which gave simultaneous $\text{S}_{\text{N}}\text{Ar}$ reaction at C4 and $\text{S}_{\text{N}}2$ at the chloroethyl side-chain to furnish tricyclic thienopyrazolopyridines. Similarly, compounds **4** on refluxing in AcOH or on heating in NH_4OAc furnished 3,6-dihydro-8-(4-chloro/4-methylphenyl)-6-phenyl-2*H*-furo[2,3-*d*]pyrazolo[3,4-*b*]pyridines **5a**, **5b** (Scheme 3). Simultaneously, the targeted new fused pyrazolo[3,4-*b*]pyrrolo[2,3-*d*]pyridines **10** were successfully synthesized in 65–85% yield from pyrazolo[3,4-*b*]pyridines **4** by neat reaction with primary aromatic amines (Scheme 3).

We have also studied the effect of a neighboring electronegative element on chemical shifts observed on ^1H NMR of compounds **3–5** and **7–10**, which showed interesting chemical shifts for $-\text{CH}_2\text{CH}_2-\text{X}$ in functional groups such as furanone, tetrahydropyran, 3-chloroethyl side-chain, and 4-hydroxyethyl ether as shown in Fig. 2, due to difference in electronegativity of the group or atom



Scheme 1





Fig. 1 Proposed mechanism for formation of tricyclic dihydrofuropyrazolopyridine in AcOH or in NH_4OAc and in POCl_3

Scheme 2



attached at the C4-position. The observed order of chemical shift is $\text{OCH}_2 > \text{NCH}_2 > \text{SCH}_2$.

Conclusions

The sodium salt of α -formyl- γ -butyrolactone is a versatile, reactive, and selective reagent giving facile reactions with primary aromatic amines at mild reaction conditions to furnish new pyrazolopyridines, pyrazolopyrrolopyridines, dihydrofuropyrazolopyridines, and thienopyrazolopyridines in fair to good yields. Strategic substitutions of the

pyrazolopyridines facilitate construction of new tricyclic fused heterocycles.

Experimental

Melting points were determined on a Gallenkamp melting point apparatus. The ^1H (300 MHz) and ^{13}C (75 MHz) NMR spectra were recorded on a Varian XL-300 spectrometer. Chemical shifts are reported in ppm relative to tetramethylsilane (TMS) and multiplicities are given as s (singlet), bs (broad singlet), d (doublet), t (triplet), q




Fig. 2 Effect of electronegative atoms on chemical shifts

(quartet) or m (multiplet). The solvents for NMR spectra were dimethyl sulfoxide (DMSO)- d_6 and $CDCl_3$ unless otherwise stated. Infrared spectra were recorded as KBr pellets on a Shimadzu FTIR-408 spectrophotometer. Mass spectra were recorded on a Shimadzu GC-MS QP 2010A mass spectrometer with ionization potential of 70 eV. Elemental analyses were performed on a Thermo Quest Flash 1112 Series EA analyzer. The reactions were monitored by thin-layer chromatography, carried out on 0.2 mm silica gel 60 F₂₅₄ (Merck) plates using ultraviolet (UV) light (254 and 366 nm) for detection. Common reagent-grade chemicals are either commercially available and were used without further purification or were prepared by standard literature procedures.

General procedure for the synthesis of compounds

3a, 3b

A mixture of the corresponding 5-aminopyrazole (0.1 mol) and 13.6 g of the sodium salt of α -formyl- γ -butyrolactone (0.1 mol) in 80 cm³ MeOH and 70 cm³ AcOH was refluxed in an oil bath for 10–12 h (TLC check, hexane–ethyl acetate 1:1). The reaction mixture was cooled to room temperature and poured into ice-cold water. The solid separated was isolated by filtration, dried, and recrystallized from toluene.

(Z)-3-[[3-(4-Chlorophenyl)-1-phenyl-1H-pyrazol-5-ylamino]methylene]dihydrofuran-2-(3H)-one

(3a, C₂₀H₁₆ClN₃O₂)

White crystalline solid; yield 23.7 g (65%); m.p.: 190–192 °C; R_f = 0.41 (hexane–ethyl acetate 1:1); IR

(KBr): $\bar{\nu}$ = 3,246 (NH), 2,959, 1,718, 1,647, 1,593, 1,564, 1,055, 1,026 cm⁻¹; ¹H NMR ($CDCl_3$): δ = 2.72 (dt, J = 8.2 Hz, 2H, CH₂), 4.19 (t, J = 8.2 Hz, 2H, CH₂), 5.56 (d, J = 9.1 Hz, 1H, NH), 6.16 (s, 1H, ArH), 7.15 (d, J = 6.2 Hz, 2H, ArH), 7.40 (m, 1H, ArH), 7.48–7.54 (m, 5H, ArH), 7.58–7.60 (d, J = 6 Hz, 2H, ArH) ppm; ¹³C NMR ($CDCl_3$): δ = 33.5, 43.1, 96.4, 99.2, 121.8, 125.7, 126.7, 128.2, 129.1, 131.9, 135.1, 137.4, 138.7, 144.0, 151.5, 168.9 ppm; MS (ESI): m/z = 365 (M⁺), 367 ([M + 2]⁺).


(Z)-Dihydro-3-[[3-(4-methylphenyl)-1-phenyl-1H-pyrazol-5-ylamino]methylene]furan-2-(3H)-one

(3b, C₂₁H₁₉N₃O₂)

White crystalline solid; yield 24.1 g (70%); m.p.: 178–180 °C; R_f = 0.40 (hexane–ethyl acetate 1:1); IR (KBr): $\bar{\nu}$ = 3,230 (NH), 2,938, 2,723, 1,722, 1,640, 1,578, 1,048 cm⁻¹; ¹H NMR ($CDCl_3$): δ = 2.41 (s, 3H, CH₃), δ = 2.81 (dt, J = 8.4 Hz, 2H, CH₂), 4.21 (t, J = 8.4 Hz, 2H, CH₂), 6.05 (d, J = 9.3 Hz, 1H, NH), 6.20 (s, 1H, ArH), 7.22 (d, J = 6 Hz, 2H, ArH), 7.39–7.42 (m, 1H, ArH), 7.44–7.53 (m, 5H, ArH), 7.73 (d, J = 6 Hz, 2H, ArH) ppm; ¹³C NMR ($CDCl_3$): δ = 20.8, 24.4, 64.8, 94.8, 97.2, 123.5, 125.1, 127.2, 129.2, 129.9, 137.3, 138.0, 138.7, 142.4, 150.4, 172.7 ppm; MS (ESI): m/z = 345 (M⁺).

General procedure for the synthesis of compounds 4 and 5 (method I)

Aminopyrazolyldihydrofuranone 3 (0.01 mol) was stirred at room temperature in 20 cm³ phosphorus oxychloride until the end of the exothermic reaction, which usually



10	Ar	R
a	<i>p</i> -ClC ₆ H ₄	C ₆ H ₅ CH ₂
b	<i>p</i> -ClC ₆ H ₄	<i>p</i> -MeC ₆ H ₄
c	<i>p</i> -ClC ₆ H ₄	4-Cl-3-FC ₆ H ₃
d	<i>p</i> -ClC ₆ H ₄	C ₆ H ₅
e	<i>p</i> -MeC ₆ H ₄	C ₆ H ₅ CH ₂
f	<i>p</i> -MeC ₆ H ₄	<i>p</i> -MeC ₆ H ₄
g	<i>p</i> -MeC ₆ H ₄	4-Cl-3-FC ₆ H ₃
h	<i>p</i> -MeC ₆ H ₄	C ₆ H ₅

Scheme 3

starts about 80–90 °C. The mixture was then refluxed further for 3–4 h. The excess POCl₃ was removed under reduced pressure. The residue obtained was stirred in ice-cold water for 2 h, and then the resulting solution was neutralized by addition of solid sodium carbonate (2–3 g). The solid separated was isolated by filtration and dried. The TLC analysis showed two products, which were separated by column chromatography using chloroform–methanol 9:1 as eluent, affording pyrazolo[3,4-*b*]pyridines **4** and 3,6-dihydro-2*H*-furo[2,3-*d*]pyrazolo[3,4-*b*]pyridines **5**.

General procedure for the synthesis of compounds **5a**, **5b** (method II)

Compound **4** (0.001 mol) was refluxed in 5 cm³ acetic acid for 2–3 h (TLC check, hexane–ethyl acetate 1:1). After completion of the reaction the mixture was cooled and poured into ice-cold water, upon which a solid separated. The solid was isolated by filtration, dried, and recrystallized from ethanol to furnish compound **5**.

General procedure for the synthesis of compounds **5a**, **5b** (method III)

A mixture of 5-aminopyrazole **1** (0.001 mol) and 0.136 g of the sodium salt of α -formyl- γ -butyrolactone (0.001 mol)

in 5 g NH₄OAc or 5 cm³ AcOH was refluxed for 10–15 h (TLC check, hexane–ethyl acetate 1:1). The reaction mixture was cooled to room temperature and poured into ice-cold water. The solid separated was filtered, dried, and recrystallized from ethanol/DMF to furnish compound **5** in 80–85% yield.

4-Chloro-5-(2-chloroethyl)-3-(4-chlorophenyl)-1-phenyl-1*H*-pyrazolo[3,4-*b*]pyridine (**4a**, C₂₀H₁₄Cl₃N₃)

Colorless crystalline solid; yield 2.41 g (60%); m.p.: 185–187 °C; *R*_f = 0.61 (chloroform–methanol 9:1); IR (KBr): $\bar{\nu}$ = 2,930, 1,601, 1,590, 1,290 cm⁻¹; ¹H NMR (CDCl₃): δ = 3.37 (t, *J* = 6.9 Hz, 2H, CH₂), 3.80 (t, *J* = 6.9 Hz, 2H, CH₂), 7.33–7.57 (m, 5H, ArH), 7.71 (d, *J* = 8.4 Hz, 2H, ArH), 8.24 (d, *J* = 8.4 Hz, 2H, ArH), 8.52 (s, 1H, ArH) ppm; ¹³C NMR (CDCl₃): δ = 33.4, 43.1, 121.8, 125.7, 126.1, 126.7, 128.2, 128.4, 129.0, 129.1, 130.7, 131.7, 135.0, 137.4, 138.7, 144.0, 151.0, 151.5 ppm; MS (ESI): *m/z* = 403 (M⁺), 405 ([M + 2]⁺), 407 ([M + 4]⁺), 409 ([M + 6]⁺).

4-Chloro-5-(2-chloroethyl)-3-(4-methylphenyl)-1-phenyl-1*H*-pyrazolo[3,4-*b*]pyridine (**4b**, C₂₁H₁₇Cl₂N₃)

White crystalline solid; yield 2.48 g (65%); m.p.: 140–142 °C; *R*_f = 0.60 (chloroform–methanol 9:1); IR (KBr): $\bar{\nu}$ = 2,942, 1,610, 1,599, 1,254 cm⁻¹; ¹H NMR (CDCl₃): δ = 2.45 (s, 3H, CH₃), 3.63 (t, *J* = 5.4 Hz, 2H, CH₂), 3.79 (t, *J* = 5.4 Hz, 2H, CH₂), 7.30–7.55 (m, 5H,

ArH), 7.60 (d, $J = 6$ Hz, 2H, ArH), 8.39 (d, $J = 6$ Hz, 2H, ArH), 8.52 (s, 1H, ArH) ppm; ^{13}C NMR (CDCl_3): $\delta = 20.9, 33.3, 43.1, 121.1, 126.1, 126.5, 126.8, 128.2, 128.8, 129.0, 129.1, 130.7, 131.6, 135.3, 137.4, 140.1, 143.0, 150.9, 151.4$ ppm; MS (ESI): $m/z = 381$ (M^+), 383 ($[\text{M} + 2]^+$), 385 ($[\text{M} + 4]^+$).

8-(4-Chlorophenyl)-3,6-dihydro-6-phenyl-2H-furo[2,3-d]pyrazolo[3,4-b]pyridine (5a, C₂₀H₁₄ClN₃O)

Crystalline cream colored solid; yields: method I: 0.104 g (30%), method II: 0.087 g (25%), method III: 0.277 g (80%); m.p.: 189–191 °C; $R_f = 0.52$ (chloroform–methanol 9:1); IR (KBr): $\bar{\nu} = 2,955, 1,602, 1,593, 1,280$ cm^{-1} ; ^1H NMR (CDCl_3): $\delta = 2.88$ (t, $J = 6.6$ Hz, 2H, CH_2), 4.27 (t, $J = 6.6$ Hz, 2H, CH_2), 7.39–7.57 (m, 5H, ArH), 7.20 (d, $J = 7.5$ Hz, 2H, ArH), 7.80 (d, $J = 7.5$ Hz, 2H, ArH), 7.89 (s, 1H, ArH) ppm; ^{13}C NMR (CDCl_3): $\delta = 27.3, 70.8, 110.4, 116.6, 121.0, 125.7, 126.5, 128.2, 128.8, 128.9, 131.5, 134.2, 139.2, 142.8, 150.3, 168.5$ ppm; MS (ESI): $m/z = 347$ (M^+), 349 ($[\text{M} + 2]^+$).

3,6-Dihydro-8-(4-methylphenyl)-6-phenyl-2H-furo[2,3-d]pyrazolo[3,4-b]pyridine (5b, C₂₁H₁₇N₃O)

Cream colored crystalline solid; yields: method I: 0.098 g (30%), method II: 0.081 g (25%), method III: 0.278 g (85%); m.p.: 197–199 °C; $R_f = 0.53$ (chloroform–methanol 9:1); IR (KBr): $\bar{\nu} = 2,955, 1,602, 1,593, 1,280$ cm^{-1} ; ^1H NMR (CDCl_3): $\delta = 2.39$ (s, 3H, CH_3), 2.78 (t, $J = 6.9$ Hz, 2H, CH_2), 4.32 (t, $J = 6.9$ Hz, 2H, CH_2), 7.09–7.46 (m, 5H, ArH), 7.29 (d, $J = 8.1$ Hz, 2H, ArH), 7.74 (d, $J = 8.1$ Hz, 2H, ArH), 8.01 (s, 1H, ArH) ppm; ^{13}C NMR (CDCl_3): $\delta = 21.1, 27.3, 70.7, 110.4, 116.7, 120.9, 126.1, 126.5, 128.7, 128.9, 129.0, 131.5, 134.2, 141.4, 143.0, 150.2, 168.7$ ppm; MS (ESI): $m/z = 327$ (M^+).

General procedure for the synthesis of compounds 6a, 6b

A solution of compound **4** (0.01 mol) and sodium ethoxide (prepared by reacting 0.27 g sodium with 50 cm^3 absolute ethanol) in 10 cm^3 ethanol was refluxed for about 9–10 h (monitored by TLC, toluene–acetone 8:2). The excess of solvent was removed under reduced pressure. The obtained solid was washed with ethanol, dried, and recrystallized from ethanol/DMF to furnish compounds **6** in good yield.

3-(4-Chlorophenyl)-5-ethenyl-4-ethoxy-1-phenyl-1H-pyrazolo[3,4-b]pyridine (6a, C₂₂H₁₈ClN₃O)

Colorless crystalline solid; yield 1.88 g (50%); m.p.: 200–202 °C; $R_f = 0.29$ (toluene–acetone 8:2); IR (KBr): $\bar{\nu} = 2,954, 2,720, 1,598, 1,580, 1,169$ cm^{-1} ; ^1H NMR (CDCl_3): $\delta = 1.35$ (t, $J = 8.4$ Hz, 3H), 3.84 (q, $J = 8.4$ Hz, 2H), 5.38 (dd, 2H), 6.79–6.92 (m, 1H), 7.11–7.38 (m, 5H, ArH), 7.62 (d, $J = 7.7$ Hz, 2H, ArH),

8.02 (d, $J = 7.7$ Hz, 2H, ArH), 8.10 (s 1H, ArH) ppm; ^{13}C NMR (CDCl_3): $\delta = 15.7, 56.4, 117.2, 118.3, 121.1, 125.3, 126.4, 127.3, 128.3, 128.8, 129.2, 130.5, 131.3, 131.5, 133.8, 134.1, 139.5, 143.2, 151.6, 158.2$ ppm; MS (ESI): $m/z = 375$ (M^+), 377 ($[\text{M} + 2]^+$).

5-Ethenyl-4-ethoxy-3-(4-methylphenyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine (6b, C₂₃H₂₁N₃O)

Colorless solid; yield 1.95 g (55%); m.p.: 218–220 °C; $R_f = 0.29$ (toluene–acetone 8:2); IR (KBr): $\bar{\nu} = 2,936, 2,722, 1,609, 1,583$ cm^{-1} ; ^1H NMR (CDCl_3): $\delta = 1.40$ (t, $J = 7.9$ Hz, 3H), 2.27 (s, 3H, CH_3) 3.78 (q, $J = 7.9$ Hz, 2H), 5.45 (dd, 2H), 6.68–6.84 (m, 1H), 7.07–7.30 (m, 5H, ArH), 7.38 (d, $J = 6.9$ Hz, 2H, ArH), 7.98 (d, $J = 6.9$ Hz, 2H, ArH), 8.04 (s 1H, ArH) ppm; ^{13}C NMR (CDCl_3): $\delta = 15.7, 21.0, 56.5, 117.4, 118.3, 121.0, 125.4, 126.5, 127.4, 128.3, 128.9, 129.2, 130.3, 131.4, 132.0, 134.1, 136.4, 140.0, 143.7, 151.9, 157.9$ ppm; MS (ESI): $m/z = 355$ (M^+).

General procedure for the synthesis of compounds 7a, 7b

To a stirred solution of **4** (0.01 mol) in DMF– H_2O (9:1), 2.60 g sodium azide (0.04 mol) was added and temperature was raised slowly to 80 °C. The mixture was kept at this temperature for about 2–2.5 h until TLC showed no more starting material. The temperature was then raised to 110 °C for 1 h. Then the solvent was removed reduced under pressure, and the oily residue was poured into ice-cold water and stirred for 1 h. The solid separated was isolated by filtration, washed with water, dried, and recrystallized from ethanol to furnish compounds **7** in good yield.

4-Azido-5-(2-chloroethyl)-3-(4-chlorophenyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine (7a, C₂₀H₁₄Cl₂N₆)

Yellow crystalline solid; yield 2.45 g (60%); m.p.: 90–92 °C; $R_f = 0.37$ (chloroform–methanol 9:1); IR (KBr): $\bar{\nu} = 2,927, 2,150, 1,620, 1,582, 1,205$ cm^{-1} ; ^1H NMR (CDCl_3): $\delta = 3.62$ (t, $J = 6.9$ Hz, 2H), 3.80 (t, $J = 6.9$ Hz, 2H), 7.25–7.52 (m, 5H, ArH), 7.18 (d, $J = 7.4$ Hz, 2H, ArH), 7.78 (d, $J = 7.4$ Hz, 2H, ArH), 7.90 (s 1H, ArH) ppm; ^{13}C NMR (CDCl_3): $\delta = 32.9, 42.3, 121.5, 125.3, 126.3, 127.9, 128.3, 128.9, 129.0, 129.2, 130.5, 131.7, 136.1, 136.8, 137.4, 144.2, 150.1, 152.3$ ppm; MS (ESI): $m/z = 408$ (M^+), 410 ($[\text{M} + 2]^+$), 412 ($[\text{M} + 4]^+$).

4-Azido-5-(2-chloroethyl)-3-(4-methylphenyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine (7b, C₂₁H₁₇ClN₆)

Yellow crystalline solid; yield 2.72 g (60%); m.p.: 110–112 °C; $R_f = 0.38$ (chloroform–methanol 9:1); IR (KBr): $\bar{\nu} = 2,945, 2,167, 1,607, 1,564, 1,227$ cm^{-1} ; ^1H

NMR (CDCl₃): δ = 2.32 (s, 3H, CH₃), 3.60 (t, J = 6.7 Hz, 2H), 3.82 (t, J = 6.7 Hz, 2H), 7.20–7.60 (m, 5H, ArH), 7.45 (d, J = 6.1 Hz, 2H, ArH), 8.00 (d, J = 6.1 Hz, 2H, ArH), 8.10 (s 1H, ArH) ppm; ¹³C NMR (CDCl₃): δ = 21.1, 33.0, 42.5, 121.6, 125.9, 126.5, 127.9, 128.5, 129.0, 129.1, 130.6, 131.7, 135.4, 136.3, 137.2, 138.9, 144.0, 149.9, 152.0 ppm; MS (ESI): m/z = 388 (M⁺), 390 ([M + 2]⁺).

General procedure for the synthesis of compounds 8a, 8b

A solution of compound **4** (0.01 mol) in 10 cm³ ethylene glycol was refluxed in presence of 0.5 cm³ triethylamine for about 5 h (TLC check, chloroform–methanol 9:1). The excess of ethylene glycol was removed under reduced pressure. The solid obtained on addition of ethanol was isolated by filtration, washed with ethanol, dried, and recrystallized from ethanol/DMF to afford **8** in good yield.

2-[5-(2-Chloroethyl)-3-(4-chlorophenyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yloxy]ethanol

(**8a**, C₂₁H₁₇Cl₂N₃O₂)

Off-white solid; yield 2.35 g (55%); m.p.: 212–214 °C; R_f = 0.76 (chloroform–methanol 9:1); IR (KBr): $\bar{\nu}$ = 3,400, 2,926, 1,593, 1,500, 1,290 cm⁻¹; ¹H NMR (CDCl₃): δ = 3.16 (t, J = 7.1 Hz, 2H), 3.46 (t, J = 7.1 Hz, 2H), 3.66–3.74 (m, 4H), 7.20–7.55 (m, 5H, ArH), 7.62 (d, J = 8.1 Hz, 2H, ArH), 8.34 (d, J = 8.1 Hz, 2H, ArH), 8.41 (s, 1H, ArH) ppm; ¹³C NMR (CDCl₃): δ = 28.8, 43.4, 60.4, 69.9, 112.1, 116.5, 121.0, 125.4, 126.5, 127.6, 128.1, 128.8, 129.0, 130.8, 131.5, 134.1, 139.2, 143.0, 150.9, 167.4 ppm; MS (ESI): m/z = 413 (M⁺), 415 ([M + 2]⁺), 417 ([M + 4]⁺).

2-[5-(2-Chloroethyl)-3-(4-methylphenyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yloxy]ethanol

(**8b**, C₂₂H₂₀ClN₃O₂)

Colorless solid; yield 2.45 g (60%); m.p.: 233–235 °C; R_f = 0.77 (chloroform–methanol 9:1); IR (KBr): $\bar{\nu}$ = 3,388, 2,902, 2,718, 1,610, 1,515, 1,278 cm⁻¹; ¹H NMR (CDCl₃): δ = 2.49 (s, 3H, CH₃), 3.13 (t, J = 7.4 Hz, 2H), 3.52 (t, J = 7.4 Hz, 2H), 3.60–3.76 (m, 4H), 7.26–7.48 (m, 5H, ArH), 7.70 (d, J = 8.2 Hz, 2H, ArH), 8.27 (d, J = 8.2 Hz, 2H, ArH), 8.37 (s, 1H, ArH) ppm; ¹³C NMR (CDCl₃): δ = 21.1, 28.7, 43.4, 60.3, 70.0, 112.3, 116.5, 121.5, 125.3, 126.5, 127.5, 127.9, 128.8, 130.1, 130.6, 131.5, 134.3, 139.0, 143.3, 150.7, 167.8 ppm; MS (ESI): m/z = 393 (M⁺), 395 ([M + 2]⁺).

General procedure for the synthesis of compounds 9a, 9b

A solution of **4** (0.01 mol) and 2.28 g thiourea (0.01 mol) in 10 cm³ acetic acid was refluxed for about 2–3 h (TLC

check, chloroform–methanol 9:1). The excess of acetic acid was removed under pressure. The obtained residue was stirred in 15 cm³ cold water. The resulting precipitated solid was isolated by filtration, washed with water, and dried to get analytically pure solid **9** in good yield. This solid product did not need further purification.

8-(4-Chlorophenyl)-3,6-dihydro-6-phenyl-2H-pyrazolo[3,4-b]thieno[2,3-d]pyridine (9a, C₂₀H₁₄ClN₃S)

White amorphous solid; yield 2.91 g (80%); m.p.: 268–270 °C; R_f = 0.72 (chloroform–methanol 9:1); IR (KBr): $\bar{\nu}$ = 2,921, 1,616, 1,545, 1,210 cm⁻¹; ¹H NMR (CDCl₃): δ = 3.30 (t, J = 6.7 Hz, 2H), 3.78 (t, J = 6.7 Hz, 2H), 7.20–7.54 (m, 5H, ArH), 7.80 (d, J = 8.5 Hz, 2H, ArH), 8.24 (d, J = 8.5 Hz, 2H, ArH), 8.30 (s, 1H, Py-H) ppm; ¹³C NMR (CDCl₃): δ = 29.6, 34.4, 121.6, 126.7, 128.7, 129.0, 130.1, 130.3, 134.9, 139.3, 143.4 ppm; MS (ESI): m/z = 363 (M⁺), 365 ([M + 2]⁺).

3,6-Dihydro-8-(4-methylphenyl)-6-phenyl-2H-pyrazolo[3,4-b]thieno[2,3-d]pyridine (9b, C₂₁H₁₇N₃S)

White amorphous solid; yield 3.10 g (90%); m.p.: 177–180 °C; R_f = 0.73 (chloroform–methanol 9:1); IR (KBr): $\bar{\nu}$ = 2,934, 2,730, 1,599, 1,545, 1,234 cm⁻¹; ¹H NMR (CDCl₃): δ = 2.45 (s, 3H, CH₃), 3.34 (t, J = 6.8 Hz, 2H), 3.86 (t, J = 6.8 Hz, 2H), 7.29–7.38 (m, 3H, ArH), 7.50–7.57 (m, 2H, ArH), 7.89 (d, J = 8.3 Hz, 2H, ArH), 8.26 (s, 1H, Py-H), 8.30 (d, J = 8.3 Hz, 2H, ArH) ppm; ¹³C NMR (CDCl₃): δ = 21.0, 29.6, 34.3, 121.6, 126.7, 128.6, 130.2, 130.3, 131.1, 135.0, 139.4, 143.4 ppm; MS (ESI): m/z = 343 (M⁺).

General procedure for the synthesis of compounds 10a–10 h

A mixture of **4** (0.01 mol) and primary aliphatic or aromatic amines (0.04 mol) was heated at 110–120 °C for about 2–3 h, until TLC showed no more starting material. Then the mixture was cooled to 20 °C and 20 cm³ cold methanol (5 °C) was added. The resulting solid was filtered by suction, washed with methanol, dried, and recrystallized from ethanol/DMF to furnish compounds **10** in good yield.

1-Benzyl-8-(4-chlorophenyl)-1,2,3,6-tetrahydro-6-phenylpyrazolo[3,4-b]pyrrolo[2,3-d]pyridine (10a, C₂₈H₂₅ClN₄)

White amorphous solid; yield 4.07 g (90%); m.p.: 179–181 °C; R_f = 0.47 (chloroform–methanol 9:1); IR (KBr): $\bar{\nu}$ = 2,908, 1,605, 1,596, 1,313, 1,090 cm⁻¹; ¹H NMR (CDCl₃): δ = 3.14 (t, J = 8.7 Hz, 2H), 3.49 (t, J = 8.7 Hz, 2H), 4.13 (s, 2H, CH₂), 7.04 (d, J = 7.8 Hz, 2H, ArH), 7.18 (d, J = 8.4 Hz, 2H, ArH), 7.23–7.31 (m, 4H, ArH), 7.49–7.57 (m, 4H, ArH), 8.14 (s, 1H, ArH), 8.29 (d, J = 7.8 Hz, 2H, ArH) ppm; ¹³C NMR (CDCl₃):

$\delta = 31.4, 43.6, 51.2, 120.1, 120.7, 121.2, 122.4, 126.2, 126.5, 127.3, 127.5, 128.2, 128.5, 129.1, 129.8, 130.1, 131.1, 133.1, 144.4, 153.1$ ppm; MS (ESI): $m/z = 452$ (M^+), 454 ($[M + 2]^+$).

8-(4-Chlorophenyl)-1,2,3,6-tetrahydro-1-(4-methylphenyl)-6-phenylpyrazolo[3,4-b]pyrrolo[2,3-d]pyridine (**10b**, $C_{27}H_{21}ClN_4$)

Off-white solid; yield 3.05 g (70%); m.p.: 192–194 °C; $R_f = 0.49$ (chloroform–methanol 9:1); IR (KBr): $\bar{\nu} = 2,950, 2,717, 1,610, 1,202$ cm^{-1} ; 1H NMR ($CDCl_3$): $\delta = 2.23$ (s, 3H, CH_3), 3.33 (t, $J = 9$ Hz, 2H), 4.18 (t, $J = 9$ Hz, 2H), 6.50 (d, $J = 8.1$ Hz, 2H, ArH), 6.80 (d, $J = 8.4$ Hz, 2H, ArH), 6.92 (d, $J = 8.4$ Hz, 2H, ArH), 7.26 (m, 2H, ArH), 7.30 (d, $J = 7.5$ Hz, 2H, ArH), 7.51 (t, $J = 7.5$ Hz, 2H, ArH), 8.22 (d, $J = 8.1$ Hz, 2H), 8.24 (s, 1H, ArH) ppm; ^{13}C NMR ($CDCl_3$): $\delta = 21.1, 31.2, 43.6, 120.1, 120.8, 121.9, 126.5, 126.7, 127.5, 128.2, 128.3, 128.7, 129.0, 129.5, 130.1, 132.5, 134.3, 140.3, 143.7, 150.8$ ppm; MS (ESI): $m/z = 434$ (M^+), 436 ($[M+2]^+$).

1-(3-Chloro-4-fluorophenyl)-8-(4-chlorophenyl)-1,2,3,6-tetrahydro-6-phenylpyrazolo[3,4-b]pyrrolo[2,3-d]pyridine (**10c**, $C_{26}H_{17}Cl_2FN_4$)

Orange amorphous solid; yield 3.56 g (75%); m.p.: 158–160 °C; $R_f = 0.49$ (chloroform–methanol 9:1); IR (KBr): $\bar{\nu} = 2,900, 1,616, 1,585, 1,240$ cm^{-1} ; 1H NMR ($CDCl_3$): $\delta = 3.20$ (t, $J = 8$ Hz, 2H), 4.26 (t, $J = 8$ Hz, 2H), 6.72 (s, 1H, Ar–H), 6.80–6.82 (m, 2H, ArH), 7.01 (d, $J = 6$ Hz, 2H, ArH), 7.26–7.45 (m, 5H, ArH), 7.89 (d, $J = 6$ Hz, 2H, ArH), 8.02 (s, 1H, ArH) ppm; ^{13}C NMR ($CDCl_3$): $\delta = 31.2, 43.4, 118.4, 120.8, 122.0, 125.8, 126.7, 127.5, 128.3, 128.7, 129.2, 129.5, 129.8, 130.2, 130.9, 131.8, 132.3, 143.4, 144.6, 151.1, 157.0$ ppm.

8-(4-Chlorophenyl)-1,2,3,6-tetrahydro-1,6-diphenylpyrazolo[3,4-b]pyrrolo[2,3-d]pyridine (**10d**, $C_{26}H_{19}ClN_4$)

White amorphous solid; yield 3.29 g (78%); m.p.: 207–209 °C; $R_f = 0.47$ (chloroform–methanol 9:1); IR (KBr): $\bar{\nu} = 2,908, 1,616, 1,598, 1,238$ cm^{-1} ; 1H NMR ($CDCl_3$): $\delta = 3.34$ (t, $J = 6.9$ Hz, 2H), 4.23 (t, $J = 6.9$ Hz, 2H), 6.78–6.84 (m, 2H, ArH), 6.88–6.92 (m, 5H, ArH), 7.32–7.34 (m, 3H, ArH), 7.52 (d, $J = 8.7$ Hz, 2H, ArH), 8.25 (d, $J = 8.7$ Hz, 2H, ArH), 8.25 (s, 1H, ArH) ppm; ^{13}C NMR ($CDCl_3$): $\delta = 31.3, 43.9, 119.8, 120.6, 121.0, 122.2, 126.4, 126.7, 127.1, 128.1, 128.5, 129.1, 129.5, 130.1, 131.1, 138.5, 143.2, 144.4, 151.3$ ppm; MS (ESI): $m/z = 422$ (M^+), 424 ($[M+2]^+$).

1-Benzyl-1,2,3,6-tetrahydro-8-(4-methylphenyl)-6-phenylpyrazolo[3,4-b]pyrrolo[2,3-d]pyridine (**10e**, $C_{28}H_{24}N_4$)

Faint brown crystalline solid; yield 3.41 g (82%); m.p.: 227–229 °C; $R_f = 0.45$ (chloroform–methanol 9:1); IR

(KBr): $\bar{\nu} = 2,934, 2,727, 1,599, 1,580, 1,338$ cm^{-1} ; 1H NMR ($CDCl_3$): $\delta = 2.24$ (s, 3H, CH_3), 3.18 (t, $J = 8.3$ Hz, 2H), 3.52 (t, $J = 8.3$ Hz, 2H), 4.16 (s, 2H, CH_2), 6.95–7.06 (m, 4H, ArH), 7.21–7.23 (m, 1H, ArH), 7.31–7.36 (m, 2H, ArH), 7.43–7.56 (m, 5H, ArH), 8.15 (s, 1H, ArH), 8.26 (d, $J = 7.6$ Hz, 2H, ArH) ppm; ^{13}C NMR ($CDCl_3$): $\delta = 21.1, 31.3, 43.5, 51.4, 120.0, 120.6, 121.2, 122.2, 126.5, 126.9, 127.3, 127.8, 128.0, 129.1, 129.4, 130.3, 131.1, 132.3, 133.5, 145.2, 152.8$ ppm; MS (ESI): $m/z = 416$ (M^+).

1,2,3,6-Tetrahydro-1,8-bis(4-methylphenyl)-6-phenylpyrazolo[3,4-b]pyrrolo[2,3-d]pyridine (**10f**, $C_{28}H_{24}ClN_4$)

Yellow solid; yield 3.33 g (80%); m.p.: 203–205 °C; $R_f = 0.48$ (chloroform–methanol 9:1); IR (KBr): $\bar{\nu} = 3,065, 2,918, 2,864, 1,593, 1,494$ cm^{-1} ; 1H NMR ($CDCl_3$): $\delta = 2.35$ (s, 3H, CH_3), 2.38 (s, 3H, CH_3), 3.27 (t, $J = 8.3$ Hz, 2H), 4.20 (t, $J = 8.3$ Hz, 2H), 6.49 (d, $J = 7.3$ Hz, 2H, ArH), 6.89–7.04 (m, 4H, ArH), 7.29 (t, $J = 6.9$ Hz, 2H, ArH), 7.37–7.40 (m, 3H, ArH), 8.14 (d, $J = 8.7$ Hz, 2H, ArH), 8.20 (s, 1H, ArH) ppm; ^{13}C NMR ($CDCl_3$): $\delta = 21.1, 21.3, 31.3, 43.3, 119.9, 120.7, 121.8, 126.4, 126.9, 127.4, 128.1, 128.5, 128.7, 129.3, 129.8, 130.4, 134.8, 136.2, 139.9, 143.9, 151.1$ ppm.

1-(4-Chloro-3-fluorophenyl)-1,2,3,6-tetrahydro-8-(4-methylphenyl)-6-phenylpyrazolo[3,4-b]pyrrolo[2,3-d]pyridine (**10g**, $C_{27}H_{20}ClFN_4$)

Colorless solid; yield 3.41 g (75%); m.p.: 160–162 °C; $R_f = 0.48$ (chloroform–methanol 9:1); IR (KBr): $\bar{\nu} = 2,949, 2,716, 1,608, 1,588$ cm^{-1} ; 1H NMR ($CDCl_3$): $\delta = 2.32$ (s, 3H, CH_3), 3.28 (t, $J = 8.8$ Hz, 2H), 4.17 (t, $J = 8.8$ Hz, 2H), 6.62 (s, 1H, ArH), 6.78 (d, $J = 7.2$ Hz, 1H, ArH), 6.83 (d, $J = 7.2$ Hz, 1H, ArH), 7.02 (d, $J = 6.9$ Hz, 2H, ArH), 7.08–7.34 (m, 5H, ArH), 8.02 (s, 1H, ArH), 8.12 (d, $J = 6.9$ Hz, 2H, ArH) ppm; ^{13}C NMR ($CDCl_3$): $\delta = 21.1, 31.2, 43.5, 118.5, 121.6, 121.9, 125.9, 126.3, 127.7, 128.3, 128.9, 129.3, 129.4, 129.8, 130.5, 131.1, 132.4, 134.9, 143.3, 144.4, 151.6, 156.8$ ppm; MS (ESI): $m/z = 455$ (M^+), 457 ($[M+2]^+$).

1,2,3,6-Tetrahydro-8-(4-methylphenyl)-1,6-diphenylpyrazolo[3,4-b]pyrrolo[2,3-d]pyridine (**10h**, $C_{27}H_{22}N_4$)

Off-white crystalline solid; yield 3.17 g (79%); m.p.: 174–176 °C; $R_f = 0.46$ (chloroform–methanol 9:1); IR (KBr): $\bar{\nu} = 2,920, 2,736, 1,596, 1,580$ cm^{-1} ; 1H NMR ($CDCl_3$): $\delta = 2.34$ (s, 3H, CH_3), 3.28 (t, $J = 8.0$ Hz, 2H), 4.22 (t, $J = 8.0$ Hz, 2H), 6.60–6.64 (m, 3H, ArH), 6.70 (d, $J = 7.8$ Hz, 2H, ArH), 7.05–7.27 (m, 5H, ArH), 7.30–7.38 (m, 2H, ArH), 8.08 (s, 1H, ArH), 8.12 (d, $J = 7.1$ Hz, 2H, ArH) ppm; ^{13}C NMR ($CDCl_3$): $\delta = 21.2, 31.4, 43.8, 120.1, 120.8, 121.0, 122.4, 126.3, 126.5, 127.0, 128.3, 128.9, 129.3, 129.5, 130.1, 134.5, 138.5, 143.6, 144.4, 151.0$ ppm.

Acknowledgments The authors thank CSIR New Delhi, India for financial support of this research project. Authors also thank the Department of Chemistry University of Pune and IIT, Powai, Mumbai for spectral and analytical facilities and the Principal KTHM College Nasik for facilities.

References

1. Sekikawa I, Nishie J, Tono-oka S, Tanaka Y, Kakimoto S (1973) *J Heterocycl Chem* 10:931
2. Kukzynski L, Mrizikiewicz A, Banaszkiwicz W, Pol K (1979) *J Pharmacol Pharm* 31:217
3. Kamal A, Atalla A, Mohamed T, Geies A (1991) *Z Naturforsch Chem Sci* 46:541
4. Chen Y (1995) International patent WO 9534563 AL 1995. *Chem Abstr* 124:232447
5. Kennis LEJ, Pieters SMA, Bischoff FP (2000) PCT Appl WO 2000020422 A1 20000413. *Chem Abstr* 132:265188t
6. Fujit H, Shimoji Y, Kojima S, Nishino H, Kamoshita K, Katsuo K, Endo K, Kobayashi S, Kumakura S, Sato Y (1977) *Sankyo Kenkysho Nenpo* 29:75
7. Kennis J, Bischoff F, Mertens C, Love C, Vanden Keybus F, Pieters S, Braeken M, Megens A, Leysen J (2000) *Bioorg Med Chem Lett* 10:71
8. Wamhoff H, Korte F (1972) *Synthesis* 151
9. Toche R, Ghotekar B, Kazi M, Jachak M, Patil S (2008) *Scholarly Res Exch* 434329. doi:10.3814/2008/434329
10. Vaidya A, Gogate V, Tilak B (1977) *Indian J Chem Sect B* 15(B):403
11. Korte F, Manchleidt H (1955) *Chem Ber* 88:136
12. Bare T, McLaren C, Campbell J, Firor J, Resch J, Walters C, Salama A, Meiners B, Patel J (1989) *J Med Chem* 32:2561
13. Joshi K, Pathak V, Garg U (1979) *J Heterocycl Chem* 16:1141
14. Zou X, Shujiang T, Feng S, Jianing X (2006) *Arkivoc* ii:130
15. Toche R, Ghotekar B, Kendre D, Kazi M, Jachak M (2008) *J Heterocycl Chem* 45:1711
16. Murray A, Murray N (1986) *Synth Commun* 16:853
17. Toche R, Ghotekar B, Kazi M, Kendre B, Jachak M (2007) *Tetrahedron* 63:8157
18. Toche R, Pagar B, Zoman R, Shinde G, Jachak M (2010) *Tetrahedron* 66:5204